AI-Guided On-Target Off-Tumor Assessment Service

Q: Q: How do you handle targets with limited published data?

Our AI uses predictive homology modeling and de novo expression simulation based on tissue-specific gene regulatory networks to provide insights even when the literature is sparse.

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides an AI-Guided On-Target Off-Tumor Assessment Service to address critical challenges in cell therapy development, including high clinical attrition due to unexpected toxicity and the lung trapping phenomenon in solid tumor CAR-T trials. This service enables evaluation of target expression across healthy tissues using integrated deep learning algorithms, high-resolution spatial transcriptomics, and large-scale cross-species proteomic databases. By delivering a detailed, data-driven safety map before clinical entry, Creative Biolabs helps de-risk therapeutic pipelines and ensures improved patient safety and target specificity.

Introduction

On-target off-tumor toxicity remains a major safety challenge in immunotherapy, arising when therapeutic targets are also expressed in normal tissues. Recent studies demonstrate that comprehensive expression profiling across healthy organs is critical for predicting adverse effects. Advances in AI and multi-omics integration now enable high-resolution analysis of tissue-specific expression patterns, supporting more accurate risk prediction. This approach improves target selection and enhances the safety profile of next-generation therapeutics.

Service

Creative Biolabs provides a comprehensive computational and analytical suite designed to predict where your therapy might strike outside the tumor microenvironment. By identifying low-level expression of targets in vital organs, often missed by traditional immunohistochemistry, we empower you to refine your candidate selection or implement logic-gate circuits to bypass healthy tissue.

Key capabilities include:

Systematic mapping of target expression across normal human tissues.
Quantitative risk scoring for off-tumor toxicity.
Comparative analysis between tumor and healthy tissue expression.
Prioritization of safe and tumor-selective targets.
Actionable recommendations for target optimization or de-selection.

Discover How We Can Help - Request a Consultation.

What We Can Offer

We integrate multiple advanced and non-proprietary technology platforms to ensure robust and reliable assessment:

Multi-Omics Data Integration	AI-Driven Expression Modeling
Bulk transcriptomics and RNA sequencing datasets. Proteomics and spatial expression data. Public and curated expression atlases for normal tissues.	Machine learning-based tissue specificity analysis. Cross-tissue expression normalization and clustering. Predictive modeling of off-tumor risk profiles.
In Silico Safety Assessment	Supporting Experimental Strategies
Target expression ranking across critical organs. Identification of high-risk tissues (e.g., lung, heart, liver). Therapeutic index estimation based on tumor vs. normal expression.	In vitro validation using human primary cells. Immunohistochemistry-based tissue cross-reactivity analysis. Flow cytometry-based target expression confirmation.

Our Workflow

Required Starting Materials: To initiate the assessment, clients typically provide the Target Antigen Sequence/Structure and the Therapeutic Modality Specifications.

Workflow of AI-Guided On-Target Off-Tumor Assessment Service. (Creative Biolabs Original)

Final Deliverables: Clients receive a Comprehensive Target Safety Atlas, including high-resolution heat maps of off-tumor expression, and a Risk Assessment Summary Report detailing predicted Maximum Tolerated Dose (MTD) ranges based on AI modeling.

Core Benefits

Customized AI Algorithm Training: We tailor our deep learning models to recognize specific post-translational modifications or conformational epitopes unique to your target.
Integrated Multi-Omics Databases: Access to exclusive, high-resolution proteomic and transcriptomic data across various healthy human developmental stages.
Predictive Organ-Trafficking Modeling: Specialized simulation of T-cell homing to identify risks of sequestration in the lungs or liver.
Logic-Gate Feasibility Assessment: Computational validation of AND-gate or NOT-gate strategies to improve tumor specificity.
Detailed Safety-Margin Quantification: Precise calculation of the therapeutic window based on predicted binding densities in healthy versus malignant tissues.

FAQs

Q: How does AI-guided assessment differ from traditional Immunohistochemistry (IHC)?

A: Traditional IHC can miss low-density antigen expression that is still high enough to trigger CAR-T activation. Our AI-guided approach utilizes deep-learning sensitivity to detect these trace expressions and predict real-world T-cell interaction dynamics.

Q: Can this service assist with logic-gate (AND/OR/NOT) CAR-T designs?

A: We specialize in identifying the optimal second antigen to pair with your primary target to ensure the therapy only activates when both are present, eliminating off-tumor risks.

Q: What types of therapeutic modalities can you assess?

A: While we specialize in CAR-T and TCR-T therapies, our AI-guided platform is equally effective for T-cell Engagers, ADCs, and monoclonal antibodies.

Q: How do you handle targets with limited published data?

A: Our AI uses predictive homology modeling and de novo expression simulation based on tissue-specific gene regulatory networks to provide insights even when the literature is sparse.

Partner with Us

Creative Biolabs provides a world-class AI-Guided On-Target Off-Tumor Assessment Service that transforms safety from uncertain clinical judgment into a predictable science, with customized AI-driven solutions enabling clients to confidently navigate the complexities of solid tumor targeting and ensure therapies effectively reach patients while maintaining high safety standards; please contact our team for more information, detailed inquiries, or to discuss your project and initiate your safety assessment.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.